A novel approach to cardiovascular health by optimizing risk management (ANCHOR): Behavioural modification inprimary care effectively reduces global risk

Canadian Journal of Cardiology

Volumn 29, Issue 11, 2013, Pages 1400-1407

  Cox, Jafna L ^a   Vallis, T Michael ^a   Pfammatter, Angela ^b   Szpilfogel, Claudine ^c   Carr, Brendan ^a   O'Neill, Blair J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Capital District Health Authority   (Canada)

^c Research Power Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMMUNITY PROGRAM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEALTH HAZARD; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SCREENING; SEX DIFFERENCE;

CANADA; CARDIOVASCULAR DISEASES; COUNSELING; FEMALE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK MANAGEMENT; RISK REDUCTION BEHAVIOR;

EID: 84886949840     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.007     Document Type: Article

References (38)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3. e442.
2. Public Health Agency of Canada. Tracking Heart Disease and Stroke in Canada. Ottawa, Ontario: Public Health Agency of Canada. Available at: Accessed December 27, 2012. http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/index-eng.php.
3. Coats A.J.S. Is preventive medicine responsible for the increasing prevalence of heart failure?. Lancet 1998, 352(suppl 1):SI39-SI41.
4. Lee D.S., Chiu M., Manuel D.G., et al. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ 2009, 181:143-149.
5. Katzmarzyk P.T., Ardern C.I. Overweight and obesity mortality trends in Canada, 1985-2000. Can J Pub Health 2004, 95:16-20.
6. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
7. Putnam W., Twohig P.L., Burge F.I., Jackson L.A., Cox J.L. Evidence-based cardiovascular care: family physicians' perspectives of obstacles and opportunities. Can Fam Physician 2004, 50:1397-1405.
8. Cox J.L., O'Neill B.J., Vallis T.M., Carr B., Szpilfogel C. ANovel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): a primary prevention initiative examining the impact of global risk factor assessment and management on health care. Can J Cardiol 2011, 27:809-817.
9. Stampfer M. Observational epidemiology is the preferred means of evaluating effects of behavioral and lifestyle modification. Control Clin Trials 1997, 18:494-499.
10. Wellsource. Available at: Accessed December 17,2012. http://www.wellsource.com/home.html.
11. McPherson R., Frohlich J., Fodor G., Genest J. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006, 22:913-927. for the Canadian Cardiovascular Society.
12. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. JAm Coll Cardiol 2010, 56:1113-1132.
13. Ruggiero L., Prochaska J.O. Readiness for change: application of the transtheoretical model to diabetes. Diabetes Spectrum 1993, 6:21-60.
14. Glasgow R.E., Bull S.S., Piette J.D., Steiner J.F. Interactive behavior change technology: a partial solution to the competing demands of primary care. Am J Prev Med 2004, 27:80-87.
15. The Nova Scotia Health Survey 1995. Available at: Accessed December 17,2012. http://www.chebucto.ns.ca/Health/Heart_Health/Survey/index.html.
16. Cooper R., Cutler J., Desvigne-Nickens P. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000, 102:3137-3147.
17. Lee I.M., Shiroma E.J., Lobelo F., et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012, 380:219-229.
18. Ebrahim S., Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2000, CD001561.
19. Sdringola S., Nakagawa K., Nakagawa Y., et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. JAm Coll Cardiol 2003, 41:263-272.
20. Appel L.J., Clark J.M., Yeh H.C., et al. Comparative effectiveness of weight loss interventions in clinical practice. NEngl J Med 2011, 365:1959-1968.
21. Reeder C.E., Divers C.H., Deem D., Cheney B.J., Fortner G., Probst L.Y. Employer-based health initiative: impact on employees' cardiovascular outcomes. AHDB 2009, 2:80-85.
22. Makrides L., Dagenais G.R., Chockalingham A., et al. Evaluation of a workplace health program to reduce coronary risk factors. Clinical Governance: An International Journal 2008, 13:95-105.
23. Villablanca A.C., Arline S., Lewis J., Raju S., Sanders S., Carrow S. Outcomes of national community organization cardiovascular prevention programs for high-risk women. JCardiovasc Trans Res 2009, 2:306-320.
24. Wister A., Loewen N., Kennedy-Symonds H., McGowan B., McCoy B., Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ 2007, 177:859-865.
25. Wood D.A., Kotseva K., Connolly S., et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008, 371:1999-2012.
26. Campbell N.C., Ritchie L.D., Thain J., Deans H.G., Rawles J.M., Squair J.L. Secondary prevention in coronary heart disease: a randomized trial of nurse-led clinics in primary care. Heart 1998, 80:447-452.
27. Rosenthal T.C. The medical home: growing evidence to support a new approach to primary care. JAm Board Fam Med 2008, 21:427-440.
28. Pearson T., Kopin L. Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol 2003, 6:204-213.
29. Butler C., Rollnick S., Stott N. The practitioner, the patient and resistance to change: recent ideas on compliance. CMAJ 1996, 154:1357-1362.
30. Blokstra A., van Dis I., Verschuren W.M. Efficacy of multifactorial lifestyle interventions in patients with established cardiovascular diseases and high-risk groups. Eur J Cardiovasc Nurs 2010, 11:97-104.
31. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD Trial. Arch Intern Med 2010, 170:1566-1575. The Look AHEAD Research Group.
32. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death a systematic review and meta-analysis of longitudinal studies. JAm Coll Cardiol 2007, 49:403-414.
33. Cooney M.T., Dudina A.L., Graham I.M. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. JAm Coll Cardiol 2009, 54:1209-1227.
34. Berry J.D., Dyer A., Cai X., et al. Lifetime risks of cardiovascular disease. NEngl J Med 2012, 366:321-329.
35. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [erratum in 2012;33:2126].
36. Weintraub W.S., Daniels S.R., Burke L.E., et al. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation 2011, 124:967-990.
37. Kessler R., Glasgow R.E. Aproposal to speed translation of healthcare research into practice: dramatic change is needed. Am J Prev Med 2011, 40:637-644.
38. Brindle P., Beswick A., Fahey T., Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006, 92:1752-1759.